A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Crohns Disease
- Colitis, Ulcerative
- Arthritis, Psoriatic
- Arthritis, Juvenile
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 3 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Janssen Research & Development, LLC
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 2
- Children's Center for Digestive Healthcare · Atlanta, GA
- Emory University · Atlanta, GA
Indiana · 1
- Riley Hospital for Children · Indianapolis, IN
Ohio · 1
- Cincinnati Children's Hospital Medical Center · Cincinnati, OH
Texas · 1
- Cook Childrens Medical Center · Fort Worth, TX
Utah · 1
- University of Utah · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.